Story preview
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →The New York Times
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
4
in the last 3 days
First reported
4 days ago
3 outlets since
Countries
3 other outlets reported this story in the last 3 days.
Anthropic’s AI-driven discovery of a new CRISPR-like enzyme system has pressured gene-editing stocks, but the technology remains at a very early stage, while CRISPR Therapeutics already has an approved therapy and multiple clinical programs.
This is not the first time that a closed-source AI model has been accused of ‘stealing’ a scientist’s work.